PTX 0.00% 4.3¢ prescient therapeutics limited

CellPryme-M question

  1. 1,456 Posts.
    lightbulb Created with Sketch. 492
    Would the incorporation of CellPryme-M into the manufacturing of an already approved (or clinically advanced) cell therapy product send that product back to phase 1 clinical trials?

    If so, CellPryme-M may only be attractive to pre-clinical or phase 1 assets.

    Anyone able to answer this question? If not, I'll email the company.
 
watchlist Created with Sketch. Add PTX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.